Advanced Search

Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2016 May 12



A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Frequency: Quarterly

ISSN 0031-0808

Online ISSN 1827-1898


Panminerva Medica 2016 May 12

The MDM2 T309G polymorphism and risk of lung cancer: an updated meta-analysis of 10186 cases and 14155 controls

Xiaodong TIAN, Bo WANG, Juntang GUO, Xi LIU, Tao ZHANG, Chaoyang LIANG, Naikang ZHOU, Xiaobin HOU, Yongfu MA, Hua YU, Lei CHEN, Zhipeng REN, Kaijie FAN, Qing TIAN

Department of Thoracic Surgery, Chinese PLA Genreral Hospital, Beijing, China

BACKGROUND: To assess the relationship between MDM2 (mouse double minute 2 homolog) T309G polymorphism and the risk and prognosis of lung cancer.
METHODS: We did a systematic review of relevant articles from EBSCO, EMBASE, Web of science, PubMed, springer link, science direct, weipu database and CNKI (Chinese National Knowledge Infrastructure)databases up to January 7, 2016.
RESULTS: Seventeen case-control studies and 5 cases prognosis were included. The results indicated that the MDM2 T309G polymorphism was associated with lung cancer risk. Subgroup analysis by ethnicity also showed that associations are significant in Asian. Five prognosis studies were also included. Patients with TT genotype had a higher survival rate at 20 months follow-up compared with those who carried TG or GG genotype (TT vs TG+GG: OR=0.34, 95% CI: 0.12-0.99, p<0.05).
CONCLUSION: MDM2 T309G polymorphism is associated with risk and prognosis of lung cancer. TT or T genotype may be associated with the reduced risk of lung cancer, especially in Asians. Meanwhile, TT genotype is also associated with the improved prognosis of the lung cancer.

language: English


top of page